Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Cambrex Reports Fourth Quarter And Full Year 2013 Financial Results

      - Strong increase in fourth quarter and full year Sales and EBITDA -

      - Expect another year of strong sales and EBITDA growth in 2014 -

      - Conference call at 8:30 a.m. ET on February 11, 2014 -


      News provided by

      Cambrex Corporation

      Feb 11, 2014, 07:00 ET

      Share this article

      Share this article


      EAST RUTHERFORD, N.J., Feb. 11, 2014 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) reports results for the fourth quarter and full year ended December 31, 2013.

      Highlights

      • Fourth quarter sales increased 46.3% to $103.0 million from $70.4 million in the same period last year.  Full year sales increased 14.1% and 12.8% excluding the impact of foreign currency.
      • Fourth quarter EBITDA increased to $22.2 million compared to $13.1 million in the same period last year.  Full year adjusted EBITDA increased 17.3% to $67.4 million compared to $57.5 million in 2012.  (See table at the end of this release).     
      • Debt, net of cash, was $56.5 million at the end of the fourth quarter, an improvement of $19.5 million during the quarter.  Debt, net of cash, increased $16.1 million for the full year 2013.
      • 2014 sales are expected to increase between 8% and 12% compared to 2013, excluding the impact of foreign currency.  EBITDA is expected to be between $70 and $76 million and adjusted income from continuing operations is expected to be between $0.99 and $1.10 per share (see Financial Expectations section below).

      "We are very pleased that 2013 was our third consecutive year of strong growth in both sales and EBITDA, and believe we are positioned to deliver a similar level of growth in 2014," commented Steven M. Klosk, President and Chief Executive Officer of Cambrex.  "We made significant growth investments during 2013 and have built the strongest pipeline of custom development projects and opportunities that we have had in many years.  In 2014, we expect to expand our footprint within our generics product category by continuing to add generic APIs to our development portfolio of 15 products, and by earmarking $2 million of additional R&D spending for projects where Cambrex expects to partner with one or more generic drug companies to co-develop finished generic drug products.

      "We are well positioned in the controlled substances market and accordingly, expect to see solid growth in this product category in 2014.  Finally, we plan to continue making targeted investments in the infrastructure of the business through capital improvements and expansions to support further growth, with expectations of strong cash flow during the year."

      Basis of Reporting 
      The Company has provided a reconciliation of GAAP amounts to adjusted (i.e. Non-GAAP) amounts at the end of this press release.  Management believes that the adjusted amounts provide useful information to investors due to the magnitude and nature of certain expenses recorded in the GAAP amounts.

      Fourth Quarter 2013 Operating Results – Continuing Operations 
      Sales of $103.0 million were 46.3% higher compared to the same period last year, including the favorable impact of foreign exchange of 1.3%.  The increase was primarily due to higher sales of a recently approved branded active pharmaceutical ingredient ("API") and controlled substances, partially offset by lower sales of generic and branded APIs and products utilizing the Company's drug delivery technology.

      Gross margins increased to 32.9% from 30.0% compared to the same period last year.  This increase was primarily due to increased sales and production volumes driving higher plant efficiencies along with a small positive impact from pricing and was partially offset by an unfavorable mix of products.

      Selling, general and administrative ("SG&A") expenses were $14.7 million compared to $11.4 million in the same period last year.  The increase was mainly due to higher personnel expenses.

      Research and development expenses were $2.8 million compared to $2.2 million in the same period last year. 

      Operating profit increased to $16.4 million from $7.4 million in the same period last year. The increase in operating profit was primarily the result of higher gross profit partially offset by higher SG&A expenses.  EBITDA was $22.2 million compared to $13.1 million in the same period last year.

      Net interest expense was $0.6 million compared to $0.5 million in the same period last year.

      Equity in losses of partially-owned affiliates, primarily representing the Company's portion of Zenara's loss, was flat at $0.5 million for both the fourth quarters of 2013 and 2012, respectively.  These amounts include amortization expense of $0.2 million for both the fourth quarters of 2013 and 2012, respectively.

      The provision for income taxes was $5.6 million and resulted in an effective tax rate of 37.4%. 

      Income from continuing operations was $9.4 million or $0.30 per share compared to $44.2 million or $1.44 per share in the same period last year.  Fourth quarter 2012 results include tax benefits of $37.6 million, or $1.22 per share, resulting from the release of a valuation allowance on deferred tax assets for $36.3 million and $1.3 million related to the impact on deferred taxes of a statutory rate change at one of our sites.

      Capital expenditures and depreciation were $9.6 million and $5.8 million, respectively, compared to $17.2 million and $5.6 million in the same period last year. 

      Financial Expectations – Continuing Operations
      The Company currently expects that full year 2014 sales, excluding the impact of foreign currency, will increase between 8% and 12% over 2013, and that full year 2014 EBITDA will be between $70 and $76 million.  The Company expects that 2014 adjusted income from continuing operations will be between $0.99 and $1.10 per share (computed on a basis consistent with 2013 and 2012 results in the table at the end of this release).  Based on current expectations regarding the timing of orders, the Company expects 2014 to start off slowly, with most of the anticipated growth coming from the second quarter and thereafter.  The Company also expects to reduce debt, net of cash, by between $25 and $30 million during 2014.

      The Company estimates that its 2014 consolidated effective tax rate will be between 33% and 37%.  In 2013, the Company began recording tax expense on U.S. income for the first time in several years.  Due to certain beneficial tax attributes, the Company currently expects to pay a small amount of cash taxes for the U.S. in 2014, however the tax rate and amount of cash taxes paid will be sensitive to the geographic mix of income, and quarterly effective tax rates may be volatile. 

      Capital expenditures for 2014 are expected to be approximately $35 to $39 million and depreciation is expected to be $25 to $27 million in 2014. 

      These financial expectations are for continuing operations and exclude the impact of any potential acquisitions, restructuring activities and outcomes of tax disputes, and sales and EBITDA expectations do not reflect the Company's stake in Zenara, which is accounted for using the equity method.  Zenara is expected to generate low single digit millions in revenues and a small EBITDA loss in 2014.

      The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the Company's 2013 Form 10-K is filed with the SEC.

      Conference Call and Webcast 
      A conference call to discuss the Company's fourth quarter and full year 2013 results will begin at 8:30 a.m. Eastern Time on Tuesday, February 11, 2014.  Those wishing to participate should call 1-888-378-0320 for domestic and +719-325-2458 for international.  Please use the pass code 8076565 and call approximately 10 minutes prior to start time.  A webcast will be available on the Investors section on the Cambrex website located at www.cambrex.com.  A telephone replay of the conference call will be available through Tuesday, February 18, 2014 by calling 1-888-203-1112 for domestic and +1-719-457-0820 for international.  Please use the pass code 8076565 to access the replay. 

      About Cambrex 
      Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit http://www.cambrex.com/www.cambrex.com.  

      Forward Looking Statements
      This document contains "forward-looking statements," including statements regarding expected performance, especially those set forth under the heading "Financial Expectations – Continuing Operations," and those attributed to our President and Chief Executive Officer in this document, including the Company's expectation that full year 2014 sales, excluding the impact of foreign currency, will increase between 8% and 12% versus 2013, that full year 2014 EBITDA will be between $70 and $76 million, that capital expenditures will be approximately $35 to $39 million, that depreciation will be between $25 and $27 million in 2014, that the Company currently expects to pay low single digit millions in cash taxes in the U.S. for 2014, that working capital levels and cash flow will improve, that the Company will spend $2 million of R&D spending related to generic drug products and that its estimated tax rate will be between 33% and 37%.  These and other forward looking statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2013, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements, including, but not limited to, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and continued demand in the U.S. for late stage clinical products or the successful outcome of the Company's investment in new products.

      For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2013, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

      Use of Non-GAAP Financial Measures
      EBITDA is a non-GAAP financial measure, which the Company defines as operating profit plus depreciation and amortization expense.  Other companies may have a different definition of EBITDA and, therefore, EBITDA may not be comparable with non-GAAP financial measures provided by other companies.  EBITDA should not be considered an alternative to measurements required by U.S. GAAP, such as net income or operating profit, and should not be considered a measure of Cambrex's liquidity.  Cambrex uses EBITDA as one of several metrics to assess and analyze its operational results and trends.  Cambrex also believes EBITDA as well as adjusted income from continuing operations are useful to investors because they are common operating performance metrics as well as metrics routinely used to assess potential enterprise value.  Cambrex has provided a reconciliation of U.S. GAAP amounts to non-GAAP amounts at the end of this press release.

      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Quarters Ended December 31, 2013 and 2012

      (in thousands, except per-share data)













      2013



      2012





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      103,011




      $

      70,389



           Commissions, Allowances and Rebates


      576





      731



      Net Sales


      102,435





      69,658













           Other


      601





      272













      Net Revenues


      103,036





      69,930













           Cost of Goods Sold


      69,098


      67.1%



      48,847


      69.4%











      Gross Profit


      33,938


      32.9%



      21,083


      30.0%











      Operating Expenses










           Selling, General and Administrative Expenses


      14,714


      14.3%



      11,419


      16.2%

           Research and Development Expenses


      2,840


      2.8%



      2,247


      3.2%

      Total Operating Expenses


      17,554


      17.0%



      13,666


      19.4%











      Operating Profit


      16,384


      15.9%



      7,417


      10.5%











      Other Expenses:










           Interest Expense, net


      595





      534



           Other Expenses, net


      107





      26



           Equity in Losses of Partially-Owned Affiliates


      605





      545













      Income Before Income Taxes


      15,077


      14.6%



      6,312


      9.0%











           Provision/(Benefit) for Income Taxes


      5,637





      (37,930)













      Income from Continuing Operations

      $

      9,440


      9.2%


      $

      44,242


      62.9%











      Loss from Discontinued Operations, Net of Tax


      (541)





      (594)













      Net Income

      $

      8,899


      8.6%


      $

      43,648


      62.0%











      Basic Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      0.31




      $

      1.48



         Loss from Discontinued Operations, Net of Tax

      $

      (0.02)




      $

      (0.02)



         Net Income

      $

      0.29




      $

      1.46













      Diluted Earnings/(Loss) per Share of Common Stock:









         Income from Continuing Operations

      $

      0.30




      $

      1.44



         Loss from Discontinued Operations, Net of Tax

      $

      (0.01)




      $

      (0.02)



         Net Income

      $

      0.29




      $

      1.42













      Weighted Average Shares Outstanding










           Basic


      30,353





      29,874



           Diluted


      31,166





      30,717



      CAMBREX CORPORATION

      Statements of Profit and Loss

      For the Twelve Months Ended December 31, 2013 and 2012

      (in thousands, except per-share data)













      2013



      2012





      % of





      % of



      Amount


      Sales



      Amount


      Sales











      Gross Sales

      $

      317,212




      $

      277,931



           Commissions, Allowances and Rebates


      1,351





      2,503



      Net Sales


      315,861





      275,428













           Other


      2,315





      1,073













      Net Revenues


      318,176





      276,501













           Cost of Goods Sold


      215,272


      67.9%



      186,014


      66.9%











      Gross Profit


      102,904


      32.4%



      90,487


      32.6%











      Operating Expenses










           Selling, General and Administrative Expenses


      47,568


      15.0%



      45,248


      16.3%

           Research and Development Expenses


      10,387


      3.3%



      9,544


      3.4%

      Total Operating Expenses


      57,955


      18.3%



      54,792


      19.7%











           Gain on Sale of Asset


      4,680


      1.5%



      -


      -











      Operating Profit


      49,629


      15.6%



      35,695


      12.8%











      Other Expenses:










           Interest Expense, net


      2,242





      2,439



           Other Expenses, net


      118





      122



           Equity in Losses of Partially-Owned Affiliates


      2,262





      1,766













      Income Before Income Taxes


      45,007


      14.2%



      31,368


      11.3%











           Provision/(Benefit) for Income Taxes


      14,732





      (31,861)













      Income from Continuing Operations

      $

      30,275


      9.5%


      $

      63,229


      22.7%











      Loss from Discontinued Operations, Net of Tax


      (4,360)





      (926)













      Net Income

      $

      25,915


      8.2%


      $

      62,303


      22.4%











      Basic Earnings/(Loss) per Share of Common Stock:










         Income from Continuing Operations

      $

      1.00




      $

      2.13



         Loss from Discontinued Operations, Net of Tax

      $

      (0.14)




      $

      (0.03)



         Net Income

      $

      0.86




      $

      2.10













      Diluted Earnings/(Loss) per Share of Common Stock:









         Income from Continuing Operations

      $

      0.98




      $

      2.09



         Loss from Discontinued Operations, Net of Tax

      $

      (0.14)




      $

      (0.03)



         Net Income

      $

      0.84




      $

      2.06













      Weighted Average Shares Outstanding










           Basic


      30,150





      29,703



           Diluted


      30,901





      30,314



      CAMBREX CORPORATION

      Consolidated Balance Sheets

      As of December 31, 2013 and 2012

      (in thousands)















      December 31,



      December 31,

      Assets


      2013



      2012







      Cash and Cash Equivalents

      $

      22,745


      $

      23,551

      Trade Receivables, net


      71,276



      43,094

      Other Receivables


      12,943



      2,015

      Inventories, net


      89,965



      71,221

      Prepaid Expenses and Other Current Assets


      5,631



      4,089

        Total Current Assets


      202,560



      143,970







      Property, Plant and Equipment, net


      171,966



      151,815

      Goodwill


      38,670



      37,312

      Intangible Assets, net


      4,011



      4,091

      Investments in and Advances to Partially-Owned Affiliates


      13,364



      15,094

      Deferred Income Taxes


      19,799



      30,786

      Other Non-Current Assets


      7,667



      2,663







        Total Assets

      $

      458,037


      $

      385,731







      Liabilities and Stockholders' Equity












      Accounts Payable

      $

      29,052


      $

      27,612

      Deferred Revenue


      20,121



      11,570

      Accrued Expenses and Other Current Liabilities


      48,098



      43,301

        Total Current Liabilities


      97,271



      82,483







      Long-Term Debt


      79,250



      64,000

      Deferred Income Taxes


      12,835



      10,383

      Accrued Pension Benefits


      40,123



      55,373

      Other Non-Current Liabilities


      18,338



      10,195







        Total Liabilities

      $

      247,817


      $

      222,434







        Stockholders' Equity

      $

      210,220


      $

      163,297







        Total Liabilities and Stockholders' Equity

      $

      458,037


      $

      385,731

      CAMBREX CORPORATION

      Reconciliation of GAAP to non-GAAP Results

      For the Quarters and Twelve Months Ended December 31, 2013 and 2012

      (in thousands)













      Fourth Quarter 2013



      Fourth Quarter 2012











      Operating Profit


      $

      16,384



      $

      7,417











      Depreciation and Amortization



      5,842




      5,641










      EBITDA


      $

      22,226



      $

      13,058



















































































      Twelve Months 2013



      Twelve Months 2012











      Operating Profit


      $

      49,629



      $

      35,695











      Gain on Sale of Asset



      (4,680)




      -











      Adjusted Operating Profit



      44,949




      35,695











      Depreciation and Amortization



      22,473




      21,775










      Adjusted EBITDA


      $

      67,422



      $

      57,470






      Twelve Months 2013


      Twelve Months 2012





      Diluted
      EPS





      Diluted
      EPS

      Income from Continuing Operations

      $

      30,275

      $

      0.98


      $

      63,229

      $

      2.09











      Stock-Based Compensation, Net of Tax1


      3,540


      0.11



      2,165


      0.07

      Gain on Sale of Asset, Net of Tax


      (3,210)


      (0.10)



      -


      -

      Amortization of Purchased Intangibles


      1,137


      0.04



      1,212


      0.04

      Reversal of Tax Valuation Allowance


      -


      -



      (36,287)


      (1.20)

      Changes in Tax Laws


      (1,155)


      (0.04)



      (1,328)


      (0.04)

      Normalization of U.S. Tax Expense2


      -


      -



      (4,575)


      (0.15)











      Adjusted Income from Continuing Operations

      $

      30,587

      $

      0.99


      $

      24,416

      $

      0.81





















      1   Tax rate estimated at 35% for stock-based compensation.

      2   Cambrex began recording tax expense in the U.S. in 2013.  2012 includes an adjustment to reflect U.S. tax
           expense at 35%.

      SOURCE Cambrex Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.